医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Fabrinet to Announce Fourth Quarter and Fiscal-Year 2021 Financial Results on August 16, 2021

2021年08月02日 PM09:30
このエントリーをはてなブックマークに追加


 

BANGKOK

Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced it will release its fourth quarter and fiscal-year 2021 financial results for the period ended June 25, 2021 after market close on Monday, August 16, 2021. On that day, management will hold a conference call and webcast at 5:00 p.m. ET to review and discuss the Company’s results.

What:   Fabrinet Fourth Quarter and Fiscal-Year 2021 Financial Results Call
When:   Monday, August 16, 2021
Time:   5:00 p.m. ET
Live Call:   (888) 357-3694, domestic
  (253) 237-1137, international
  Passcode: 2199846
Replay:   (855) 859-2056, domestic
  (404) 537-3406, international
  Passcode: 2199846
Webcast:   https://investor.fabrinet.com/ (live and replay)

A recorded version of this webcast will be available approximately two hours after the call and accessible at https://investor.fabrinet.com/. The webcast will be archived on Fabrinet’s website for a period of one year.

About Fabrinet

Fabrinet is a leading provider of advanced optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and subsystems, automotive components, medical devices, industrial lasers and sensors. Fabrinet offers a broad range of advanced optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, advanced packaging, integration, final assembly and testing. Fabrinet focuses on production of high complexity products in any mix and any volume. Fabrinet maintains engineering and manufacturing resources and facilities in Thailand, the United States of America, the People’s Republic of China, Israel and the United Kingdom. For more information visit: www.fabrinet.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005156/en/

CONTACT

Investor Contact:

Garo Toomajanian

ir@fabrinet.com

同じカテゴリーの記事 

  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続
  • ReNAgade Therapeutics继续致力于GanNA Bio和糖生物学的研究